The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

A medication called omalizumab (often sold as Xolair) has been around for a long time and was used to help deal with asthma.

In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

The Johns Hopkins-led OUtMATCH study, which enrolled clinical trial participants at 10 locations across the U.S., leads to ...

In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever ...

Omalizumab mechanism of action. Omalizumab binds to the Ce3 domain of immunoglobulin E (lgE) and prevents free lgE from binding to the mast cell FceRI receptor. Data courtesy of Genentech ...

During the 24-week study, patients received Dupixent 300 mg every two weeks or omalizumab 75 to 600 mg every two or four weeks, which was added to background MFNS.